Income Taxes - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Income Taxes [Line Items]
Non-deductible premium paid on the conversion of the 2024 Notes		$ 379,900
Current federal tax expense	$ 5,064	4,180	$ 0
Current state tax expense	19,748	11,111	13,193
Valuation allowance	(888,335)	(883,665)
Net operating loss carried forwards	67,594	154,948
Federal Orphan Drug Tax Credits	301,900
Accrual for interest or penalties	0	0
Recognized interest and/or penalties	$ 0	$ 0	$ 0
Minimum [Member]
Income Taxes [Line Items]
Operating loss carryforwards, ending of expiration year	2025
Maximum [Member]
Income Taxes [Line Items]
Operating loss carryforwards, ending of expiration year	2041
Federal [Member]
Income Taxes [Line Items]
Current federal tax expense	$ 5,100
Net operating loss carryforwards	134,900
Net operating loss carryforwards subject to expiration	69,100
Net operating loss carried forwards	65,800
State [Member]
Income Taxes [Line Items]
Current state tax expense	19,700
Valuation allowance	(890,600)
Net operating loss carryforwards	354,800
Net operating loss carryforwards subject to expiration	341,000
Net operating loss carried forwards	13,800
Foreign [Member]
Income Taxes [Line Items]
Net operating loss carryforwards	$ 13,500
Research and Development Credits [Member]
Income Taxes [Line Items]
Research and development credits carryforward, Description	These federal and state research and development credits expire between 2034 and 2044 and between 2031 and 2039, respectively.
Research and Development Credits [Member] | Federal [Member]
Income Taxes [Line Items]
Research and development	$ 40,900
Research and Development Credits [Member] | State [Member]
Income Taxes [Line Items]
Research and development	$ 48,900